Does Cannabis Legalization Spur More Innovation Than Medical Research?
The announcement of the rescheduling of medical cannabis products this week has been one of the most significant policy shifts in the U.S. cannabis industry and broader drug policy in years, which is set to potentially ease barriers for researchers who study cannabis.The Department of Justice and the Drug Enforcement Administration moved cannabis products approved by the Food and Drug Administration and products covered by qualifying state medical cannabis licenses to the Schedule III category u...
Filters & Sorting